New drug combo trial offers hope for advanced lung cancer patients
NCT ID NCT05904379
Summary
This study is testing the safety and effectiveness of two immunotherapy drugs, AK112 and AK104, given with or without standard chemotherapy, for people with advanced non-small cell lung cancer. It aims to see if this combination can better control the cancer and help patients live longer. The trial is for adults with advanced-stage cancer who have not had certain genetic mutations.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Conditions
Explore the condition pages connected to this study.